试论名词性复合词的意义建构

名词性复合词的意义建构是一个看似简单,实际上非常复杂的过程。传统语法把这一意义建构成过程简单化,认为名词性复合词的意义等于各组成部分名词的意义总和。转换生成语言学家、意义特征理论学家也都提出了各自的理论解释,但都有很大的缺陷。概念合成语言学理论对名词性复合词的意义建构做出了比较完整的理论解释,但也有待于进一步的改进。     

稀土氨基酸配合物对小白鼠生长的影响

本文试验了稀土氨基酸配合物对小白鼠生长的影响。结果表明，对小白鼠饲用５０ｐｐｍ和２００ｐｐｍ的稀土氨基酸配合物饲料可提高其增重速度，促进其生长发育。且５０ｐｐｍ组的增重速度高于２００ｐｐｍ组。     

R_2O、SO_3对回转窑硅酸盐水泥熟料煅烧和质量的影响

本文论述了SO3、R2O挥发性微组合化合物对水泥回转窑及窑尾预分解工艺系统结皮的影响,探讨了消除窑后结圈的措施,论述了R2O、SO3微组合化合物对回转窑内生料易烧性,以及对熟料强度、凝结时间、安定性、水化热、需水量的不利影响,并提出相应对策措施．     

基于语料库的英语新词认知语义研究——以“碳族复合词”为例

在认知语言学领域,日渐增多的语言学家开始意识到语言现象的研究应基于语言使用。认知语义研究可以从语料库所提供的大量真实的语言材料中获益。本研究以当代美国英语语料库为数据来源,以carbon构成的“碳族复合词”为考察对象,拟从认知语言学的概念隐喻角度对英语新词新义背后的认知机制做出深入分析,从而以该个案展示基于语料库的认知语义研究的可行性。     

相对论效应对含碘复合物非键作用的影响研究

本文通过几个简单含碘复合物的相对论密度泛函计算,考察了相对论效应对碘键作用的影响。最后结果表明相对论效应对碘键作用影响较小,一般计算时可以忽略,采用pbeO／6—311G^＊或pvDZ、pvTZ基组可以很好地描述含碘复合物,而选择好的相关能方法则是成功计算相对论效应的关键。     

释"曹"

"曹"字的甲骨文形体为上"(東東)"下"口"的会意字,"曹"字的字形义为以言词审理原告被告双方的诉讼.<说文>对"曹"的形体分析"从(東東),在廷东",不确.     

关于几类有机化合物命名原则的探讨

从有机化学命名中的次序规则和最低系列原则出发，对某些有机化合物如卤代烃和胶类化合物的命名原则进行了一些探讨．     

菊花中7种化合物HPLC检测方法的建立

建立同时检测菊花中7种化合物HPLC方法。采用乙腈-0.1%磷酸水溶液梯度洗脱,流速:0.8mL/min,进样量:10μL,检测波长:348nm,柱温:30℃,同时检测绿原酸、木犀草苷、3,5-0-二咖啡酰基奎宁酸、芦丁、黄芩苷、槲皮素和金合欢素等7种化合物。HPLC法图谱比较,发现6种不同菊花7种化合物成分峰面积比例具有很大差异。试验结果表明,该方法能够简便、灵敏、直观地揭示不同菊花的差异,为菊花的指纹图谱建立和菊花多成分的含量测定提供参考方法。     

A Cognitive Study of Word-formation of Chinese New Metaphorical Compounds

A great deal of new words are emerging and coming into vogue.Most of the previous studies on Chinese new words focused on their classification,form and meaning,as well as the social motivations.This thesis chooses to study the concept metaphor of Chinese new metaphorical compounds from the cognitive perspective based on 396 new words in 2010 and aims to classify the new metaphorical words in a new way and pay attention to the analysis of word formation of new metaphorical compounds.Besides,this paper attempts to explore the understanding process of metaphorical new words.     

New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy

Infection with hepatitis C virus (HCV) affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care (SOC) involving pegylated interferon-α (PEG-IFN α) plus ribavirin (RBV) for 48 weeks results in a sustained virologic response in less than 50% of patients with chronic hepatitis C genotype 1, the most prevalent type of HCV in North America and Europe. Recently, reliable in vitro culture systems have been developed for accelerating antiviral therapy research, and many new specifically targeted antiviral therapies for hepatitis C (STAT-C) and treatment strategies are being evaluated in clinical trials. These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration. The aim of this review is to summarize the current developments in new anti-HCV drugs.